Of the 11 branded drugs in BPH/urinary disorder treatment, Harnal had the highest usage rate at 78%, followed by Flivas (75%) and Avolve (50%). For the rate of product awareness, the highest was Harnal and the second highest was Urief (Daiichi-Sankyo). (See graph below) As for future usage rate of main products that the respondents expect to increase, Avolve was specifically high, followed by Urief (Kissei), Urief (Daiichi-Sankyo), and Flivas. Also, 30% of the respondents have plans to start using a new product within the next six months.
- Target samples: N=370 with internal medicine doctors and urologists
- Study period: May ~ June 2014
- Studied products: Harnal, Flivas, Urief (Kissei), Urief (Daiichi-Sankyo), Ebrantil, Prostal L, Perselin, Avolve, Eviprostat, Cernilton, Zalutia
- Studied items: average monthly number of patients and prescriptions, product awareness and usage rates, product satisfaction, the reasons for use, future usage expectations (short-term), intentions of switching, rate of not switching to generic products, and reasons for adopting new products